Literature DB >> 18039100

VEGF-A and the induction of pathological angiogenesis.

Janice A Nagy1, Ann M Dvorak, Harold F Dvorak.   

Abstract

Tumors, wounds, and chronic inflammatory disorders generate a new vascular supply by a process known as pathological angiogenesis. Whereas formation of the normal blood vasculature requires the interaction of many different agonists and inhibitors, including vascular endothelial growth factor-A (VEGF-A) and other members of the vascular permeability factor/VEGF family, pathological angiogenesis is a cruder, simpler process that can be replicated by a single VEGF-A isoform, VEGF-A(164/5). VEGF-A(164/5) induces the formation of several distinctly different types of new blood vessels that differ from normal blood vessels with respect to organization, structure, and function. Elucidating the properties of these new vessels has led to a better understanding of angiogenesis and will hopefully lead to new approaches to antiangiogenic therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18039100     DOI: 10.1146/annurev.pathol.2.010506.134925

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  159 in total

1.  Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy.

Authors:  Basel Sitohy; Janice A Nagy; Shou-Ching Shih Jaminet; Harold F Dvorak
Journal:  Cancer Res       Date:  2011-09-21       Impact factor: 12.701

Review 2.  NFAT, immunity and cancer: a transcription factor comes of age.

Authors:  Martin R Müller; Anjana Rao
Journal:  Nat Rev Immunol       Date:  2010-08-20       Impact factor: 53.106

3.  Differential Expression of Vascular Endothelial Growth Factor-A165 Isoforms Between Intracranial Atherosclerosis and Moyamoya Disease.

Authors:  Hao Jiang; Juan F Toscano; Michael Schiraldi; Shlee S Song; Konrad H Schlick; Oana M Dumitrascu; Raymond Liou; Patrick D Lyden; Jianwei Pan; Renya Zhan; Jeffrey L Saver; Nestor R Gonzalez
Journal:  J Stroke Cerebrovasc Dis       Date:  2018-11-02       Impact factor: 2.136

4.  Transgenic insulin-like growth factor-1 stimulates activation of COX-2 signaling in mammary glands.

Authors:  Jie Tian; Isabel Lambertz; Thomas R Berton; Joyce E Rundhaug; Kaoru Kiguchi; Stephanie H Shirley; John Digiovanni; Claudio J Conti; Susan M Fischer; Robin Fuchs-Young
Journal:  Mol Carcinog       Date:  2011-10-17       Impact factor: 4.784

5.  Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase.

Authors:  Qi Xue; Janice A Nagy; Eleanor J Manseau; Thuy L Phung; Harold F Dvorak; Laura E Benjamin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-05-14       Impact factor: 8.311

Review 6.  Endogenous endothelial cell signaling systems maintain vascular stability.

Authors:  Nyall R London; Kevin J Whitehead; Dean Y Li
Journal:  Angiogenesis       Date:  2009-01-27       Impact factor: 9.596

7.  Non-invasive dynamic near-infrared imaging and quantification of vascular leakage in vivo.

Authors:  Steven T Proulx; Paola Luciani; Annamari Alitalo; Viviane Mumprecht; Ailsa J Christiansen; Reto Huggenberger; Jean-Christophe Leroux; Michael Detmar
Journal:  Angiogenesis       Date:  2013-01-17       Impact factor: 9.596

Review 8.  The roles of ADAMTS in angiogenesis and cancer.

Authors:  Yi Sun; Jintuan Huang; Zuli Yang
Journal:  Tumour Biol       Date:  2015-04-28

9.  Direct inhibition of hypoxia-inducible transcription factor complex with designed dimeric epidithiodiketopiperazine.

Authors:  Katherine M Block; Hui Wang; Lajos Z Szabó; Nathan W Polaske; Laura K Henchey; Ramin Dubey; Swati Kushal; Csaba F László; Joshua Makhoul; Zuohe Song; Emmanuelle J Meuillet; Bogdan Z Olenyuk
Journal:  J Am Chem Soc       Date:  2009-12-23       Impact factor: 15.419

10.  Secreted frizzled-related protein 4: an angiogenesis inhibitor.

Authors:  Ajit Muley; Syamantak Majumder; Gopi Krishna Kolluru; Steve Parkinson; Helena Viola; Livia Hool; Frank Arfuso; Ruth Ganss; Arun Dharmarajan; Suvro Chatterjee
Journal:  Am J Pathol       Date:  2010-01-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.